Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.48 |
| ▸ | MAP2 | P11137 | 9/20 | 0.48 |
| ▸ | RHEB | Q15382 | 3/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347844 | 0.88 | MAP2 (0.56) | MCL1MAP2RHEBRAB9AKDM4E | |
| SCHEMBL10775994 | 0.87 | MCL1 (0.58) | MCL1MAP2KDM4EALDH1A1HPGD | |
| SCHEMBL2349784 | 0.86 | MAP2 (0.51) | MCL1MAP2KDM4EALDH1A1GAA | |
| SCHEMBL2346633 | 0.86 | MAP2 (0.49) | MAP2KDM4EALDH1A1HPGD | |
| SCHEMBL3840006 | 0.81 | MCL1 (0.41) | MCL1RHEBBRD4RAB9ANR4A2 | |
| SCHEMBL2348968 | 0.76 | MAP2 (0.55) | MAP2NR4A2KDM4EALDH1A1GAA | |
| SCHEMBL10773951 | 0.76 | MCL1 (0.56) | MCL1KDM4EALDH1A1HPGD | |
| SCHEMBL2343430 | 0.75 | MAP2 (0.48) | MAP2ALDH1A1 | |
| SCHEMBL18160172 | 0.75 | CCNB2 (0.53) | RHEBKDM4E | |
| SCHEMBL2730936 | 0.74 | MAP2 (0.60) | MAP2NR4A2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008340-B2 | 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2011-08-30 | — | — | US | claimed |
| EP-1791537-B1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2009-10-14 | — | — | EP | claimed |
| US-20070142454-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | claimed |
| EP-1791537-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006023590-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-8008340-B2 | 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1791537-B1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20070142454-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1791537-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006023590-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142454-A1 | 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE I | CSNK1A1, CSNK1E, CSNK1D | MCL1 4596/4885MAP2 160/4885RHEB 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.